The Orsiro Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stent: A Review of Current Evidence
Highlights
- • Numerous trials have shown Orsiro to be safe and effective.
- • Orsiro has shown favorable performance in high-risk subgroups.
- • BIOSTEMI trial has shown superiority in the ACS population.
Abstract
Advances in stent design and the development of bioresorbable polymers have allowed the development of novel stent technologies such as the Orsiro bioresorbable-polymer sirolimus eluting stent (BP-SES). Over several noninferiority trials, the BP-SES has demonstrated itself to be a safe and effective therapy for obstructive coronary artery disease. This article reviews the current evidence of the efficacy of the BP-SES and examines its performance in high-risk populations, such as patients presenting with ST-segment myocardial infarction, chronic total occlusions, diabetes, and small vessel disease.